You are here

EICOSAPENTAENOIC ACID FOR TOPICAL SKIN DISEASE TREATMENT

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: N/A
Agency Tracking Number: 16343
Amount: $500,000.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1992
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
Box 20159
Seattle, WA 98102
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Winget, Rodner R
 Principal Investigator
 (206) 439-7588
Business Contact
 1 R43 AR40645-01A1
Phone: () -
Research Institution
N/A
Abstract

THE LONG TERM GOAL OF THIS PROJECT IS TO PROVIDE AN ACTIVE INGREDIENT FOR TOPICAL TREATMENT OF SKIN DISEASES, ESPECIALLY PSORIASIS, ACNE, ECZEMA, AND ATOPIC DERMATITIS. THE SPECIFIC AIM IS TO (1) DEVELOP THE CHEMISTRY FOR ISOLATING A SPECIES OF LIPID FROM MARINE ALGAE THAT CONTAIN HIGH CONCENTRATIONS OF EICOSAPENTAENOIC ACID (EPA), (2) IDENTIFY THE STRUCTURE OF THE PRODUCT BY CHEMICAL AND SPECTRAL MEANS, AND (3) TEST THE EFFECTIVENESS OF THIS PRODUCT, WHICH WILL CARRY THE TRADE NAME DERMEPA, ON CELL PROLIFERATION IN HUMAN SKIN GRAFTED TO NUDE MICE, USING RADIOTRACER TECHNOLOGY AND ON EDEMA IN MOUSE EARS. THE TECHNICAL INNOVATION IS ISOLATION, FOR THE FIRST TIME, OF A SPECIES OF LIPID FROM ALGAE THAT MAY BE A SUPERIOR TOPICAL DELIVERY SYSTEM OF EPA. THE PROCESS WILL BE CONSIDERED SAFE BY THE FOOD AND DRUG ADMINISTRATION FOR MARKETING DERMEPA AS AN ETHICAL DRUG. THE DISEASES TARGETED AFFECT APPROXIMATELY 14 MILLION PEOPLE IN THE UNITED STATES.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government